 HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., July 13, 2021 GLOBE NEWSWIRE -- HUTCHMED China Limited HUTCHMED NasdaqAIM: HCM; HKEX: 13 announces the first commercial sale in China of ORPATHYS savolitinib, HUTCHMEDs oral, potent, and highly selective small molecule inhibitor of MET, a receptor tyrosine kinase, which occurred on July 12, 2021. 